Given that the majority of breast cancer is initially positive for steroid hormone receptors (64), blockade of CDK4/6 activity by small molecule inhibitors represents a rational strategies and has proven efficacious in the treatment of breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.